Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42319   clinical trials with a EudraCT protocol, of which   6970   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3b, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

    Summary
    EudraCT number
    2019-003554-86
    Trial protocol
    DE   DK   GB   FR   NL  
    Global end of trial date
    17 May 2021

    Results information
    Results version number
    v1(current)
    This version publication date
    29 Nov 2021
    First version publication date
    29 Nov 2021
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX19-445-116
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04353817
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Jun 2021
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    17 May 2021
    Global end of trial reached?
    Yes
    Global end of trial date
    17 May 2021
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in subjects 6 through 11 years of age with cystic fibrosis (CF), heterozygous for F508del and a minimal function (MF) mutation (F/MF).
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    19 Jun 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 11
    Country: Number of subjects enrolled
    Canada: 13
    Country: Number of subjects enrolled
    Israel: 5
    Country: Number of subjects enrolled
    Denmark: 3
    Country: Number of subjects enrolled
    France: 14
    Country: Number of subjects enrolled
    Germany: 31
    Country: Number of subjects enrolled
    Netherlands: 7
    Country: Number of subjects enrolled
    Spain: 8
    Country: Number of subjects enrolled
    Switzerland: 12
    Country: Number of subjects enrolled
    United Kingdom: 17
    Worldwide total number of subjects
    121
    EEA total number of subjects
    63
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    121
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    This study was conducted in CF subjects 6 through 11 years of age.

    Period 1
    Period 1 title
    Triple Combination Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Subjects received placebo matched to ELX/TEZ/IVA in the treatment period for 24 weeks.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo (matched to ELX/TEZ/IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to ELX/TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    Placebo (matched to IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to IVA once daily in the evening.

    Arm title
    ELX/TEZ/IVA
    Arm description
    Subjects received ELX/TEZ/IVA in the treatment period for 24 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    ELX/TEZ/IVA
    Investigational medicinal product code
    VX-445/VX-661/VX-770
    Other name
    Elexacaftor/Tezacaftor/Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received ELX/TEZ/IVA fixed-dose combination once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Number of subjects in period 1
    Placebo ELX/TEZ/IVA
    Started
    61
    60
    Completed
    61
    59
    Not completed
    0
    1
         Adverse Event
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to ELX/TEZ/IVA in the treatment period for 24 weeks.

    Reporting group title
    ELX/TEZ/IVA
    Reporting group description
    Subjects received ELX/TEZ/IVA in the treatment period for 24 weeks.

    Reporting group values
    Placebo ELX/TEZ/IVA Total
    Number of subjects
    61 60 121
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    9.2 ± 1.7 9.1 ± 1.8 -
    Gender categorical
    Units: Subjects
        Female
    35 35 70
        Male
    26 25 51

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to ELX/TEZ/IVA in the treatment period for 24 weeks.

    Reporting group title
    ELX/TEZ/IVA
    Reporting group description
    Subjects received ELX/TEZ/IVA in the treatment period for 24 weeks.

    Primary: Absolute Change in Lung Clearance Index (LCI) 2.5

    Close Top of page
    End point title
    Absolute Change in Lung Clearance Index (LCI) 2.5
    End point description
    LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
    End point type
    Primary
    End point timeframe
    From Baseline Through Week 24
    End point values
    Placebo ELX/TEZ/IVA
    Number of subjects analysed
    61
    60
    Units: lung clearance index
        least squares mean (standard error)
    -0.02 ± 0.16
    -2.29 ± 0.16
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Placebo v ELX/TEZ/IVA
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Mixed-effects Model for Repeated Measure
    Parameter type
    Least Squares (LS) Mean Difference
    Point estimate
    -2.26
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.71
         upper limit
    -1.81

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to Week 28
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    24.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to ELX/TEZ/IVA in the treatment period for 24 weeks.

    Reporting group title
    ELX/TEZ/IVA
    Reporting group description
    Subjects received ELX/TEZ/IVA in the treatment period for 24 weeks.

    Serious adverse events
    Placebo ELX/TEZ/IVA
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 61 (14.75%)
    4 / 60 (6.67%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Investigations
    Bacterial test positive
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Phimosis
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Nasal polyps
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Lymphadenitis
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    General physical health deterioration
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Intussusception
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Distal intestinal obstruction syndrome
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    3 / 61 (4.92%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia pseudomonal
         subjects affected / exposed
    1 / 61 (1.64%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Varicella zoster virus infection
         subjects affected / exposed
    0 / 61 (0.00%)
    1 / 60 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo ELX/TEZ/IVA
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    53 / 61 (86.89%)
    46 / 60 (76.67%)
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    3 / 61 (4.92%)
    5 / 60 (8.33%)
         occurrences all number
    4
    9
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 61 (1.64%)
    3 / 60 (5.00%)
         occurrences all number
    2
    3
    Bacterial test positive
         subjects affected / exposed
    4 / 61 (6.56%)
    0 / 60 (0.00%)
         occurrences all number
    4
    0
    Forced expiratory volume decreased
         subjects affected / exposed
    4 / 61 (6.56%)
    0 / 60 (0.00%)
         occurrences all number
    4
    0
    Staphylococcus test positive
         subjects affected / exposed
    1 / 61 (1.64%)
    4 / 60 (6.67%)
         occurrences all number
    1
    4
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    26 / 61 (42.62%)
    14 / 60 (23.33%)
         occurrences all number
    40
    17
    Nasal congestion
         subjects affected / exposed
    3 / 61 (4.92%)
    3 / 60 (5.00%)
         occurrences all number
    4
    3
    Nasal polyps
         subjects affected / exposed
    4 / 61 (6.56%)
    0 / 60 (0.00%)
         occurrences all number
    5
    0
    Oropharyngeal pain
         subjects affected / exposed
    12 / 61 (19.67%)
    3 / 60 (5.00%)
         occurrences all number
    14
    4
    Productive cough
         subjects affected / exposed
    6 / 61 (9.84%)
    7 / 60 (11.67%)
         occurrences all number
    7
    8
    Rhinorrhoea
         subjects affected / exposed
    7 / 61 (11.48%)
    7 / 60 (11.67%)
         occurrences all number
    7
    9
    Nervous system disorders
    Headache
         subjects affected / exposed
    12 / 61 (19.67%)
    18 / 60 (30.00%)
         occurrences all number
    20
    22
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    5 / 61 (8.20%)
    0 / 60 (0.00%)
         occurrences all number
    5
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    17 / 61 (27.87%)
    5 / 60 (8.33%)
         occurrences all number
    27
    9
    Diarrhoea
         subjects affected / exposed
    6 / 61 (9.84%)
    4 / 60 (6.67%)
         occurrences all number
    6
    4
    Abdominal pain upper
         subjects affected / exposed
    5 / 61 (8.20%)
    4 / 60 (6.67%)
         occurrences all number
    7
    4
    Nausea
         subjects affected / exposed
    5 / 61 (8.20%)
    1 / 60 (1.67%)
         occurrences all number
    6
    1
    Steatorrhoea
         subjects affected / exposed
    0 / 61 (0.00%)
    3 / 60 (5.00%)
         occurrences all number
    0
    4
    Vomiting
         subjects affected / exposed
    4 / 61 (6.56%)
    3 / 60 (5.00%)
         occurrences all number
    4
    4
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    0 / 61 (0.00%)
    4 / 60 (6.67%)
         occurrences all number
    0
    5
    Rash
         subjects affected / exposed
    3 / 61 (4.92%)
    6 / 60 (10.00%)
         occurrences all number
    3
    6
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    4 / 61 (6.56%)
    1 / 60 (1.67%)
         occurrences all number
    4
    2
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    14 / 61 (22.95%)
    1 / 60 (1.67%)
         occurrences all number
    16
    1
    Nasopharyngitis
         subjects affected / exposed
    9 / 61 (14.75%)
    7 / 60 (11.67%)
         occurrences all number
    12
    8
    Rhinitis
         subjects affected / exposed
    5 / 61 (8.20%)
    3 / 60 (5.00%)
         occurrences all number
    5
    3
    Upper respiratory tract infection
         subjects affected / exposed
    5 / 61 (8.20%)
    3 / 60 (5.00%)
         occurrences all number
    8
    4

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA